Cargando…

Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study

INTRODUCTION: Tables predicting the probability of a positive bone scan in men with non-metastatic, castrate-resistant prostate cancer have recently been reported. We performed an external validation study of these bone scan positivity tables. MATERIALS AND METHODS: We performed a retrospective coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnston, Ashley W., Longo, Thomas A., Davis, Leah Gerber, Zapata, Daniel, Freedland, Stephen J., Routh, Jonathan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Urologia 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968912/ https://www.ncbi.nlm.nih.gov/pubmed/31851457 http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0225

Ejemplares similares

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
por: Moreira, Daniel M., et al.
Publicado: (2015)

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH
por: Hanyok, Brian T., et al.
Publicado: (2019)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer
por: Anand, Aseem, et al.
Publicado: (2022)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
por: Song, Hualin, et al.
Publicado: (2020)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Bone marrow involvement in patients with metastatic castration sensitive prostate cancer
por: Shahait, Mohammed, et al.
Publicado: (2022)

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
por: Nakano, Kazuhiko, et al.
Publicado: (2014)

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
por: Yang, Yun-Jie, et al.
Publicado: (2018)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide
por: Anand, Aseem, et al.
Publicado: (2016)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids
por: Lee, Sanghee, et al.
Publicado: (2022)

Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium‐223
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2015)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Evaluation of selective bone scan staging in prostate cancer – external validation of current strategies and decision-curve analysis
por: Hiwase, Mrunal D., et al.
Publicado: (2022)

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
por: Frieling, Jeremy S., et al.
Publicado: (2023)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
por: Uemura, Koichi, et al.
Publicado: (2016)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
por: McNamara, Megan A, et al.
Publicado: (2015)

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD
por: de Wit, Ronald, et al.
Publicado: (2022)

Liver uptake on bone scan for prostate cancer metastatic workup
por: Mukendi, Alain Mwamba
Publicado: (2019)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Development and external validation of a prostate health index-based nomogram for predicting prostate cancer
por: Zhu, Yao, et al.
Publicado: (2015)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
por: LeVee, Alexis, et al.
Publicado: (2021)

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
por: Nickols, Nicholas G., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vgs6kfv6rljo5k6ccufbf4frgb